Bionano Genomics, Inc. (BNGO) Income Statement
BNGO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBNGO revenue and net income
Where BNGO's revenue goes
2025Each bar shows an amount and its share of revenue. BNGO kept −92.6% of revenue as net income.
BNGO profit margins
BNGO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −7.4% | +0.8% | +27.4% | — |
| Gross profit | +1,546.8% | +1.7% | +17.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BNGO quarterly EPS vs estimates
Bionano Genomics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.56).
BNGO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M | $9.5M | $6.8M |
| Cost of revenue | $22.2M | $30.4M | $26.6M | $21.9M | $14.1M | $5.7M | $6.8M | $8.7M | $6.0M | $3.6M |
| Gross profit | $6.3M | $380,000 | $9.6M | $5.9M | $3.9M | $2.8M | $3.4M | $3.3M | $3.5M | $3.2M |
| Research & development | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M | $10.3M | $9.1M | $9.5M | $12.0M | $11.4M |
| Sales, general & admin | $35.1M | $51.9M | $93.5M | $88.6M | $58.5M | $31.1M | $20.2M | $14.2M | $14.1M | $13.0M |
| Total operating expenses | $39.6M | $104.4M | $224.8M | $137.6M | $81.0M | $41.3M | $29.2M | $23.7M | $26.1M | $24.4M |
| Operating income | −$33.3M | −$104.0M | −$215.2M | −$131.7M | −$77.1M | −$38.6M | −$25.9M | −$20.4M | −$23.2M | −$21.2M |
| Interest income | $4.9M | $2.1M | $3.3M | $1.5M | $236,000 | $0 | $2.3M | $1.4M | $590,930 | $470,070 |
| Interest expense | $298,000 | $289,000 | $5.1M | $298,000 | $927,000 | $2.5M | $2.3M | $1.4M | $590,927 | $470,072 |
| Income before taxes | −$26.3M | −$112.0M | −$232.4M | −$130.7M | −$78.2M | −$41.1M | −$29.8M | −$18.5M | −$23.3M | −$18.8M |
| Income taxes | $67,000 | $33,000 | $62,000 | $1.9M | −$5.7M | $29,193 | $21,048 | $15,511 | $18,552 | $12,924 |
| Net income | −$26.4M | −$112.0M | −$232.5M | −$132.6M | −$72.4M | −$41.1M | −$29.8M | −$18.5M | −$23.4M | −$18.8M |
| EBITDA | −$16.3M | −$97.5M | −$213.6M | −$120.8M | −$73.9M | −$37.1M | −$24.7M | −$15.8M | −$21.3M | −$17.3M |
| EPS (diluted) | −$4.74 | −$67.59 | −$207.85 | −$198.13 | −$104.72 | −$102.35 | −$882.77 | −$666.71 | −$4.47 | — |
| Gross margin | 22.0% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% | 36.6% | 47.3% |
| Operating margin | −116.9% | −337.9% | −596.0% | −473.7% | −428.8% | −453.4% | −255.4% | −170.1% | −244.3% | −311.6% |
| Net margin | −92.6% | −364.0% | −643.7% | −476.9% | −402.8% | −483.8% | −294.5% | −154.1% | −245.8% | −277.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $6.7M | $8.0M | $7.4M | $6.7M | $6.5M | $8.2M | $6.1M | $7.8M | $8.8M | $10.7M | $9.3M |
| Cost of revenue | $3.9M | $3.4M | $4.6M | $4.0M | $3.3M | $3.5M | $4.7M | $14.5M | $5.2M | $5.9M | $8.3M | $6.6M |
| Gross profit | $4.3M | $3.3M | $3.4M | $3.4M | $3.5M | $2.9M | $3.4M | −$8.4M | $2.6M | $2.8M | $2.4M | $2.7M |
| Research & development | $3.0M | $3.1M | $3.2M | $2.8M | $2.9M | $2.4M | $3.5M | $4.7M | $6.8M | $9.8M | $11.7M | $13.8M |
| Sales, general & admin | $8.5M | $8.0M | $8.7M | $9.1M | $8.3M | $9.0M | $11.7M | $9.5M | $11.6M | $19.5M | $15.7M | $24.9M |
| Total operating expenses | $11.5M | $11.1M | $11.9M | $11.9M | $11.3M | $11.4M | $15.4M | $35.5M | $19.6M | $33.9M | $22.5M | $116.0M |
| Operating income | −$7.2M | −$7.9M | −$8.5M | −$8.5M | −$7.8M | −$8.5M | −$11.9M | −$43.9M | −$17.0M | −$31.1M | −$20.0M | −$113.2M |
| Interest income | $146,000 | $223,000 | $167,000 | $268,000 | $277,000 | $290,000 | $225,000 | $376,000 | $457,000 | $1.0M | $1.2M | $730,000 |
| Interest expense | $359,000 | $72,000 | $72,000 | $69,000 | $73,000 | $85,000 | $27,000 | $68,000 | $74,000 | $122,000 | $4.9M | $71,000 |
| Income before taxes | −$7.4M | −$8.3M | −$7.9M | −$8.5M | −$6.8M | −$3.1M | −$20.1M | −$44.2M | −$16.2M | −$31.4M | −$43.9M | −$112.5M |
| Income taxes | $7,000 | $10,000 | $35,000 | $14,000 | $10,000 | $7,000 | $1,000 | $24,000 | $26,000 | −$18,000 | −$36,000 | $39,000 |
| Net income | −$7.4M | −$8.3M | −$7.9M | −$8.5M | −$6.9M | −$3.1M | −$20.1M | −$44.2M | −$16.2M | −$31.4M | −$43.9M | −$112.6M |
| EBITDA | −$5.1M | −$5.9M | −$5.4M | −$6.0M | −$4.3M | −$525,000 | −$17.6M | −$38.5M | −$12.8M | −$23.6M | −$35.4M | −$108.8M |
| EPS (diluted) | −$0.64 | −$0.75 | −$0.03 | −$1.59 | −$1.97 | −$1.15 | −$7.73 | −$16.05 | −$13.33 | −$30.48 | −$0.96 | −$60.49 |
| Gross margin | 52.8% | 48.6% | 42.7% | 45.7% | 51.6% | 45.5% | 41.9% | −139.1% | 33.3% | 32.2% | 22.7% | 29.5% |
| Operating margin | −88.3% | −118.1% | −107.4% | −115.9% | −115.8% | −131.1% | −146.3% | −722.9% | −219.0% | −354.9% | −186.9% | −1,215.0% |
| Net margin | −90.8% | −124.2% | −99.8% | −115.4% | −101.8% | −48.0% | −246.5% | −728.6% | −208.8% | −358.3% | −409.4% | −1,208.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BNGO's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BNGO financial results
In fiscal year 2025 (ended December 31, 2025), Bionano Genomics reported revenue of $28.5 million, down 7.4% from the year before. It had a net loss of $26.4 million, a net profit margin of −92.6%. Diluted earnings per share came to −$4.74. Over five years revenue grew at an average rate of 27.4% a year.
See the BNGO stock overview for the latest quote and news, or the BNGO chart for price history and technical indicators.
BNGO income statement FAQ
What is Bionano Genomics's annual revenue?
Bionano Genomics reported total revenue of $28.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 7.4% from $30.8 million the previous year.
Is Bionano Genomics profitable?
No. Bionano Genomics reported a net loss of $26.4 million in fiscal 2025, a net profit margin of −92.6%; its operating margin was −116.9%.
What is Bionano Genomics's gross margin?
Bionano Genomics's gross margin was 22.0% in fiscal 2025: for every $100 of revenue, Bionano Genomics kept $22 after the direct cost of its products and services.
How much does Bionano Genomics spend on research and development?
Bionano Genomics spent $11.4 million on research and development in fiscal 2025, 39.9% of revenue.
How fast is Bionano Genomics growing?
Revenue grew 27.4% a year on average over the last five fiscal years, from $8.5 million to $28.5 million.
What are Bionano Genomics's earnings per share?
Bionano Genomics earned $-4.74 per diluted share in fiscal 2025, compared with $-67.59 a year earlier.
When will Bionano Genomics report its next earnings?
Bionano Genomics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Bionano Genomics's fiscal year end?
Bionano Genomics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.